Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label study of EMB-01 in recurrent metastatic colorectal cancer
CTR20254128Phase 2Active
- Sponsor
- EpimAb Biotherapeutics
- Start
- Dec 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of emb-01 in colorectal cancer (CRC) (2 arms), sponsored by EpimAb Biotherapeutics. Primary endpoints: Objective response rate, Safety profile and 1 more. Started Dec 2025; status: active.
02
Drugs
emb-01
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20254128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254128.